Edgar Filing: CELL THERAPEUTICS INC - Form 4

Form 4	RAPEUTICS INC	C								
December 12										
FORM	N OMB	PPROVAL 3235-0287								
Check this box Washington, D.C. 20549								Number:	January 31,	
if no long subject to Section 1 Form 4 or	6. SIAIE N	IENT O	WNERSHIP OF	Expires: Estimated burden hou response	2005 average urs per					
Form 5 obligation may cont <i>See</i> Instru 1(b).	ns Section 17(a) of the	Public U	tility Hol	ding Cor		nge Act of 1934, of 1935 or Secti 940			
(Print or Type F	Responses)									
1. Name and Address of Reporting Person <u>*</u> Plunkett Matthew			Symbol	er Name an o		c	5. Relationship of Reporting Person(s) to Issuer			
			CELL [THERAP	EUTICS	INC	(Check all applicable)			
				of Earliest T	ransaction		Director 10% Owner X Officer (give title Other (specify			
3101 WEST 600	ERN AVENUE,	SUITE		IOHUH/IJAV/ICAL)				below) below) EVP, Corporate Development		
				4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
(City)	(State)	(Zip)	Tah	le I - Non-l	Derivative	Securities A	Person	of. or Beneficia	lly Owned	
1.Title of	2. Transaction Date	24 Deem		3.	4. Securit			6. Ownership	7. Nature of	
	(Month/Day/Year)	Execution any	Date, if	Transactio Code (Instr. 8)	onAcquired Disposed (Instr. 3, 4	(A) or of (D)	Securities Beneficially Owned	Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Rep	ort on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
·	·				Perso inform requir	ons who re nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	
	Tab					posed of, or convertible	Beneficially Owner securities)	i		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: CELL THERAPEUTICS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		(Month/Day/Year)		(Instr. 3 and 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 1.77	12/10/2013		А		300,000		<u>(1)</u>	12/10/2023	Common Stock	300,000

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121			EVP, Corporate Dev	velopment
Signatures				
Louis A. Bianco, Attorney-in-fact for Mat Plunkett	thew	12	/12/2013	
**Signature of Reporting Person			Date	
Explanation of Pospons	001			

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Such option vests in two equal installments on 12/10/2013 and 6/10/2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.